These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 3648856)

  • 1. [Immunological profile of drug addicts: HTLV-III negative, HTLV-III positive and those with lymphadenopathy syndrome-AIDS related complex].
    Cascavilla N; Martini E; Melillo L; Musto P; Nobile M; Valori VM; Di Giorgio G; Carotenuto M
    Recenti Prog Med; 1987 Mar; 78(3):108-12. PubMed ID: 3648856
    [No Abstract]   [Full Text] [Related]  

  • 2. [Occurrence of HTLV-III infection and related clinical forms in a homogeneous group of drug addicts. Significance of immunologic changes and evaluation of risk factors].
    Tassinari MC; Gualandi M; Guerra G; Barbieri D; Benassi N; Lazzarato M; Dallara G; Gallerani M
    Recenti Prog Med; 1986 Oct; 77(10):461-5. PubMed ID: 3547522
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunological abnormalities in intravenous drug abusers and relationship to the prolonged generalized lymphadenopathy syndrome in Italy.
    De Paoli P; Reitano M; Battistin S; Martelli P; Villalata D; Bergamo F; Tirelli U; Carbone A; Diodato S; Bosio R
    Clin Exp Immunol; 1986 Jun; 64(3):451-6. PubMed ID: 3024880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Milan as possible starting point of LAV/HTLV III epidemic among Italian drug addicts.
    Lazzarin A; Crocchiolo P; Galli M; Uberti Foppa C; Caredda F; Re T; Moroni M
    Boll Ist Sieroter Milan; 1987; 66(1):9-13. PubMed ID: 3304347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevalence of antibodies against HTLV-III/LAV in homosexuals and drug addicts from a population in Madrid].
    Alós JI; Rodríguez-Créixems M; Guerrero A; Gómez-Criado C; Romero-Vivas J; Bouza E
    Rev Clin Esp; 1986 Sep; 179(4):172-4. PubMed ID: 3464056
    [No Abstract]   [Full Text] [Related]  

  • 6. [Significance of neopterin, gamma interferon and other immunologic parameters determined in a population of drug addicts, positive or negative for anti-HTLV III antibodies].
    Soffritti E; Dallara G; Bernardoni R; Ferrari R; Pelizzola D; Cicognani I; Gallerani M; Colamussi V; Cazzuffi S; Scaglianti G
    G Clin Med; 1987 Feb; 68(2):87-95. PubMed ID: 3111926
    [No Abstract]   [Full Text] [Related]  

  • 7. A clinical-immunological evaluation of AIDS cases and related syndromes.
    Gritti FM; Raise E; Gualandi G; Bonazzi L; Martuzzi M; Schiattone ML; Di Pede B; Gallo R; Rivano MT; Taruscio D
    J Exp Pathol; 1987; 3(4):723-36. PubMed ID: 3483882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between immunodeficiency conditions and AIDS-associated retrovirus (ARV) infection in homosexual men and i.v. drug abusers in the Campania Region.
    Castello G; Melillo G; D'Alessio V; Leonardi E; Zarrilli D; Cataldo PT; Chirianni A; de Mercato R; Piazza M
    Haematologica; 1986; 71(6):453-7. PubMed ID: 3104152
    [No Abstract]   [Full Text] [Related]  

  • 9. [HTLV-III serology, epidemiology and clinical aspects of imprisoned i.v. drug-dependent males in Austria].
    Pont J; Neuwald C; Kunz C; Werdenich W
    Wien Klin Wochenschr; 1986 Jul; 98(14):454-7. PubMed ID: 3019019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunological abnormalities in intravenous drug addicts in relation to contact with the HTLV III/LAV virus].
    Besalduch Vidal J; Sanchís Cervera J; Miralles Bacete E; Vila Pastor B; Balaguer Muñoz H; Gil García S
    Med Clin (Barc); 1987 May; 88(18):715-8. PubMed ID: 3497319
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of HTLV III/LAV and other viral antibodies in normal and at risk populations.
    Ferrante P; Nardi G; Zanchetta N; Salvioni PM; Pagano A
    Boll Ist Sieroter Milan; 1986; 65(5):357-60. PubMed ID: 3030363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [AIDS: an assessment of the potential occupational risk in the dental environment for HIV (human immunodeficiency virus) infection].
    Avoni A; Borea G; Chiodo F; Costigliola P; Ricchi E
    Minerva Stomatol; 1986 Oct; 35(10):941-6. PubMed ID: 3467166
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases.
    Robert-Guroff M; Oleske JM; Connor EM; Epstein LG; Minnefor AB; Gallo RC
    Pediatr Res; 1987 Jun; 21(6):547-50. PubMed ID: 3474582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies anti-HTLV III and lymphocyte subsets of high risk subjects.
    Ripa S; Mignini F; Anichini M; Casprini P; Prenna M
    Boll Ist Sieroter Milan; 1987; 66(2):101-5. PubMed ID: 3663335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological survey of HIV infection in the Veneto region of Italy.
    Chieco Bianchi L; Faulkner Valle G; De Rossi A; Dalla Gassa O
    Biomed Pharmacother; 1987; 41(3):139-43. PubMed ID: 3038208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiologic and clinical study of HIV infection in Cagliari].
    Farci P; Lai ME; Orgiana G; Chessa L; Casula P; Arnone M; Bolasco P; Bolasco F; Altieri P; Balestrieri A
    Recenti Prog Med; 1987 Dec; 78(12):539-42. PubMed ID: 3502504
    [No Abstract]   [Full Text] [Related]  

  • 17. [Case reports of 77 HTLV III/LAV-positive patients observed during one-year period. Preliminary note].
    Soranzo ML; Salassa B; Daziano E; Paggi GC
    Minerva Med; 1986 May; 77(20):897-900. PubMed ID: 3014379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential reactivities of antibodies to HIV and HTLV-I in sera of suspected AIDS and ARC patients.
    Aidoo M; Nishiwaki O; Akari H; Brandful JA; Ampofo W; Hayami M; Ayisi NK
    West Afr J Med; 1994; 13(3):150-1. PubMed ID: 7841103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevalence of antibodies against HTLV-III in the at risk population in Madrid. Clinical study and incidence of virologic markers].
    González Lahoz JM; Gutiérrez Angulo MT; Polo Rodríguez R; Subirats Núñez M; Moreno Celda V; Baquero Mochales M
    Rev Clin Esp; 1987 May; 180(8):416-9. PubMed ID: 3649830
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidemiological aspects of HTLV-III infection in Italy.
    Rossi P; Carbonari M; Bonomo R; Galli M; Manconi PE; Scarpati B; Scano G; Gaetano C; Ensoli B; Aiuti F
    Eur J Epidemiol; 1985 Dec; 1(4):288-93. PubMed ID: 3879841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.